FDA Expands Pfizer's Hympavzi Approval to New Hemophilia Patient Groups
PFE is trading near its 52-week low of $23.08 (12% above the low).
Summary
The U.S. FDA has approved an expanded indication for Pfizer's hemophilia drug, Hympavzi, to include two additional patient populations: individuals aged 12 and older with inhibitors and children aged 6-11. This regulatory approval broadens the market for Hympavzi, enhancing its revenue potential within the rare disease segment. This positive development adds to Pfizer's recent string of favorable news, including strong Phase 2b results for its obesity drug candidate and positive Phase 3 results for its Talzenna and Xtandi combination therapy.
At the time of this announcement, PFE was trading at $25.96 on NYSE in the Life Sciences sector, with a market capitalization of approximately $148.4B. The 52-week trading range was $23.08 to $28.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.